Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/ijms221910557
Keywords
combination therapy; metformin; olaparib; ovarian cancer; PARP inhibitor; replication stress
Funding
- Department of Medical Biophysics of University of Lodz [B1811000000190.01]
Ask authors/readers for more resources
This study demonstrated that the combination treatment of olaparib and metformin had a significant inhibitory effect on HR-proficient ovarian cancer cells, inducing apoptosis by increasing ROS levels. The synergistic effect was observed in cells with mutant or null p53, providing a new approach for the treatment of gynecologic cancers. The results support the use of metformin to enhance the sensitivity of EOC to olaparib therapy.
This study examined the effect of combination treatment with the poly (ADP-ribose) polymerase inhibitor olaparib and metformin on homologous recombination (HR)-proficient epithelial ovarian cancer (EOC). Ovarian cancer cell lines (OV-90 and SKOV-3) were treated with olaparib, metformin, or a combination of both. Cell viability was assessed by MTT and colony formation assays. The production of reactive oxygen species (ROS) and changes in mitochondrial membrane potential were examined using the specific fluorescence probes, DCFH2-DA (2 & PRIME;,7 & PRIME;-dichloro-dihydrofluorescein diacetate) and JC-1 (5,5 & PRIME;,6,6 & PRIME;-tetrachloro-1,1 & PRIME;,3,3 & PRIME;-tetraethylbenzimidazolcarbocyanine). Apoptotic and necrotic changes were measured by double staining with Hoechst 33258 and propidium iodide, orange acridine and ethidium bromide staining, phosphatidylserine externalization, TUNEL assay, caspase 3/7 activity, and cytochrome c and p53 expression. Compared with single-drug treatment, the combination of olaparib and metformin significantly inhibited cell proliferation and colony formation in HR-proficient ovarian cancer cells. ROS production preceded a decrease in mitochondrial membrane potential. The changes in ROS levels suggested their involvement in inducing apoptosis in response to combination treatment. The present results indicate a shift towards synergism in cells with mutant or null p53, treated with olaparib combined with metformin, providing a new approach to the treatment of gynecologic cancers. Taken together, the results support the use of metformin to sensitize EOC to olaparib therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available